Bacterial therapy:a promising strategy for cancer immunotherapy  

作　　者：Yinsong Wang 

机构地区：[1]The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics,Key Laboratory of Immune Microenvironment and Disease(Ministry of Education),Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics(Theranostics),School of Pharmacy,Tianjin Medical University,Tianjin 300070,China

出　　处：《Cancer Biology & Medicine》2023年第11期795-798,共4页癌症生物学与医学（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Grant Nos.82273499 and 81972903);the Talent Excellence Program from Tianjin Medical University。

摘　　要：Cancer immunotherapy is capable of stimulating the body's immune system to selectively attack cancer cells and has the advantages of high efficacy and low toxicity over traditional therapies.Numerous immunotherapies have been approved for clinical applications or clinical trials,including immune checkpoint blockade,adoptive cell therapy,recombinant cytokines,bispecific T-cell engagers,and cancer vaccines.

关 键 词：IMMUNOTHERAPY CLINICAL CANCER 

分 类 号：R730.5[医药卫生—肿瘤]